RESUMEN

Multiple myeloma (MM) is a malignancy with excessive production of monoclonal proteins. At disease presentation 30% of MM patients have significant renal impairment which may progress to renal failure requiring dialysis. Besides chemotherapy extracorporeal elimination procedures such as plasma exchange have been applied as adjuvant strategies to eliminate free light chains from circulating blood, however the efficacy was poor with older techniques. We report about a highly efficient method to eliminate serum free light chain (sFLC) using a newly designed protein leaking membrane in patients suffering from sFLC induced acute renal failure. The protein leaking membrane (HCO 1100) is characterized by increased pore size facilitating elimination of middle molecules such as sFLC kappa (22.5 kD). The HCO 1100 membrane was applied in a hemodialysis and hemodiafiltration mode and compared to standard procedures (high flux hemodialysis, hemodiafiltration and plasma exchange). Hemodiafiltration with the protein leaking membrane HCO 1100 was superior to all other extracorporeal replacement strategies in eliminating sFLC-kappa from circulating blood. A median blood reduction rate of 40.8% (range 13.9%-66.4%) was achieved during hemodiafiltration. The corresponding peak clearance rate was 25 ml/min. Importantly, the poorest elimination rate was achieved by plasma exchange followed by standard high flux hemodialysis. Extracorporeal elimination strategies with the protein leaking membrane HCO 1100 may be a promising adjuvant treatment strategy for patients with sFLC nephropathy requiring dialysis. Hemodiafiltration and to lesser extend also hemodialysis with the HCO 1100 hemofilter are able to eliminate substantial amounts of sFLC kappa in MM patients.

Asunto(s)

Lesión Renal Aguda/terapia , Hemodiafiltración/métodos , Cadenas kappa de Inmunoglobulina/sangre , Mieloma Múltiple/terapia , Lesión Renal Aguda/etiología , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/complicaciones

RESUMEN

PURPOSE: A novel type of adsorptive plasma filtering device (ETX-A) capable of removing endotoxin from blood in a single step has recently been developed using nanotechnology. METHODS: In a miniaturized, ex vivo model of extracorporeal circuits, we tested the capacity to reduce plasma cytokine concentration of ETX-A filters in comparison to standard high-flux (HF) filters, high cut-off (HCO) filters and a control. Blood from six healthy volunteers was spiked with endotoxin and then circulated through closed (ETX-A, control) or open (HF, HCO) circuits. Blood flow was set at 16 ml/min and filtration flow at 1 ml/min. Samples for measurement of IL-1ra and IL-6 were taken at baseline and at 4 hours. RESULTS: Compared to control (703.3 [850.6] pg/mL), in HCO (383.5 [1144.1] pg/mL) and ETX-A (490.1 [683.2] pg/mL) filters, plasma IL-1ra pooled pre- and postfilter concentrations were lower at the end of the experiment (P=0.002; P=0.050, respectively) whereas, in standard HF filters, IL-1ra concentration was higher than control. HCO showed a trend toward a reduced relative increase in IL-6 concentration from commencement to end of experiment compared to control (P=0.07). After pooling end-of-experiment plasma cytokine values of novel blood purification devices, we found HCO + ETX-A superior to H with regard to reduction of IL-1ra (-27.0 [-20.5]% vs. 8.1 [18.9]%; p<0.001) and IL-6 (-18.0 [38.3]% vs. -1.1 [24.3]%; P=0.050) compared to control. CONCLUSIONS: HCO and ETX-A appeared to significantly reduce plasma IL-1ra and, when combined, plasma IL-6 concentration as well. It appears desirable to manufacture full-size blood purification devices using this technology and to explore their effect on cytokine removal.

Asunto(s)

Endotoxemia/terapia , Hemofiltración/instrumentación , Proteína Antagonista del Receptor de Interleucina 1/sangre , Interleucina-6/sangre , Lipopolisacáridos/sangre , Miniaturización , Adulto , Endotoxemia/inmunología , Diseño de Equipo , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo

RESUMEN

The use of citrate as an anticoagulant in continuous renal replacement therapy is an effective method to achieve regional anticoagulation of the extracorporeal blood circuit and to avoid systemic anticoagulation. This allows bleeding complications to be reduced and filter life time to be prolonged. However, citrate enters the systemic circulation and is metabolized in the liver to bicarbonate, causing metabolic alkalosis in some patients. In this case report, we discuss therapeutic interventions to control the acid-base status and to restore normal pH during continuous citrate hemodialysis.

Asunto(s)

Lesión Renal Aguda/terapia , Alcalosis/terapia , Anticoagulantes/efectos adversos , Citratos/efectos adversos , Soluciones para Hemodiálisis/administración & dosificación , Diálisis Renal , Equilibrio Ácido-Base , Lesión Renal Aguda/metabolismo , Lesión Renal Aguda/fisiopatología , Anciano , Alcalosis/inducido químicamente , Alcalosis/metabolismo , Alcalosis/fisiopatología , Anticoagulantes/administración & dosificación , Anticoagulantes/metabolismo , Bicarbonatos/sangre , Citratos/administración & dosificación , Citratos/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Hígado/metabolismo , Masculino , Flujo Sanguíneo Regional , Factores de Tiempo

RESUMEN

BACKGROUND: The Genius dialysis system is increasingly used as an intermittent hemodialysis device in the setting of acute renal failure. Slow extended hemodialysis is preferred in the case of critical ill patients. In this study we established a safe and feasible citrate anticoagulation protocol for slow extended hemodialysis (SLED) with the Genius system. METHODS: We compared six anticoagulation protocols using SLED in 34 critically ill patients with acute renal failure. One group (A) received only citrate anticoagulation. Four groups (B - D) were treated with citrate and different additional systemic anticoagulation. Patients in the last group (F) were anticoagulated with heparin and were free of citrate anticoagulation. The total number of treatments was 103. A 4% sodium citrate solution was infused into the arterial line of the dialysis device for citrate anticoagulation. The dialysis solution contained one mmol/L of calcium. No additional calcium supplementation was done. We monitored electrolyte, acid-base and cardiovascular status prospectively. RESULTS: Hemodialysis was well tolerated hemodynamically. Electrolytes remained stable throughout hemodialysis in all groups. The decrease in ionized and total calcium was within the expected, clinically acceptable range. Bicarbonate and pH levels increased during dialysis, especially if citrate was used. CONCLUSIONS: Slow extended Genius hemodialysis with citrate is well tolerated and offers a safe and effective alternative to systemic anticoagulation.

Asunto(s)

Lesión Renal Aguda/terapia , Anticoagulantes/uso terapéutico , Ácido Cítrico/uso terapéutico , Soluciones para Hemodiálisis , Diálisis Renal/métodos , Anciano , Estudios de Factibilidad , Femenino , Fondaparinux , Soluciones para Hemodiálisis/química , Soluciones para Hemodiálisis/uso terapéutico , Heparina de Bajo-Peso-Molecular/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Polisacáridos/uso terapéutico , Diálisis Renal/instrumentación , Resultado del Tratamiento

RESUMEN

PURPOSE: Evaluation of a new standardised ultrasound (US) technique for diagnosis of acute rejection of kidney grafts. MATERIALS AND METHODS: Twenty-two kidney recipients underwent US examination following administration of 1.6 ml US contrast medium (USCM, SonoVue) 6 days after kidney transplantation. The examinations were performed with the Aplio US system (Toshiba). The difference in time to the first increase in signal intensity between the renal artery and the renal cortex was determined. Subsequently, the temporal course of contrast enhancement in the area of the renal artery following the first peak was recorded over 10 sec and depicted in colour using a Windows-based software. The resulting colour-time-images were evaluated by three readers who rated the images on an analogue scale from 1 (normal) to 5 (abnormal). RESULTS: 12 of the 22 patients had an uneventful clinical course. US demonstrated rapid inflow of the USCM into the renal cortex. The calculated time difference was 1.0 +/- 0.4 sec. The score assigned to the parametric images was 1.7 +/- 0.8. 8 of the 22 patients underwent biopsy and showed histologically proven rejection. The time difference in the rejection group was twice as high as in the normal group (2.2 +/- 0.7 sec, p < 0.05). The scores were in the abnormal range (3.7 +/- 1.6, p < 0.05). Two patients with perirenal haematoma also had high scores, without rejection. CONCLUSIONS: Acute rejection and perirenal haematoma are associated with a delayed signal increase in the renal cortex. This information can be provided with a single image with standardised colour display of the temporal course of USCM inflow.

Asunto(s)

Rechazo de Injerto/diagnóstico por imagen , Aumento de la Imagen/métodos , Procesamiento de Imagen Asistido por Computador/métodos , Trasplante de Riñón/diagnóstico por imagen , Arteria Renal/diagnóstico por imagen , Ultrasonografía Doppler en Color/métodos , Adolescente , Adulto , Anciano , Artefactos , Biopsia , Velocidad del Flujo Sanguíneo/fisiología , Medios de Contraste/administración & dosificación , Femenino , Rechazo de Injerto/patología , Hematoma/diagnóstico por imagen , Humanos , Corteza Renal/irrigación sanguínea , Corteza Renal/diagnóstico por imagen , Corteza Renal/patología , Pruebas de Función Renal , Trasplante de Riñón/patología , Masculino , Persona de Mediana Edad , Fosfolípidos , Programas Informáticos , Hexafluoruro de Azufre , Resistencia Vascular/fisiología

RESUMEN

BACKGROUND: The use of trisodium-citrate for regional anticoagulation of the extracorporal circuit during renal replacement therapy (RRT) has received increased interest, particularly in critically ill patients with increased risk of bleeding. Continuous renal replacement therapies are the most extensively investigated and used procedures in this regard. However, when patients recover from critical illness, RRT is often switched to intermittent procedures. In this prospective study, we investigated the efficacy and safety of citrate anticoagulation during intermittent hemodialysis (IHD) performed with a standard roller blood pump device. METHODS: We treated 11 critically ill patients with acute renal failure. These patients received a total of 31 intermittent IHD treatments. The targeted IHD treatment time was 6 h (4.5 l/h treatment dose). For anticoagulation, a 4% trisodium-citrate solution was continuously infused into the arterial line of the extracorporeal circuit. A calcium-free, lactate-based dialysis solution was used in all treatment procedures. Calcium was continuously substituted via a separate central line. Electrolyte and acid-base changes as well as the cardiovascular hemodynamics were analyzed. RESULTS: All patients achieved the targeted filter life time. Filter clotting did not occur. Electrolytes and acid base values were well-maintained throughout the study period. Particularly metabolic derangements were not observed. All treatments were hemodynamically well-tolerated. CONCLUSIONS: Intermittent hemodialysis with citrate anticoagulation can be safely applied in critically ill patients at high risk of bleeding.

Asunto(s)

Anticoagulantes/efectos adversos , Ácido Cítrico/efectos adversos , Diálisis Renal/efectos adversos , Equilibrio Ácido-Base/efectos de los fármacos , Anticoagulantes/farmacología , Coagulación Sanguínea/efectos de los fármacos , Calcio/metabolismo , Ácido Cítrico/farmacología , Electrólitos , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Resultado del Tratamiento

RESUMEN

PURPOSE: beta2-microglobulin (beta2MG) is pivotal to the pathogenesis of dialysis-related amyloidosis. We compared the effects of high cut-off hemodialysis (HCO-HD) with those of standard high-flux hemodialysis (HF-HD) regarding the concentration and clearance of beta2MG and albumin. DESIGN: We enrolled ten patients with acute renal failure in a double-blind, cross-over, randomized controlled trial. PROCEDURES: Each patient received four hours of HCO-HD (estimated in vivo cutoff 50-60 kDa) and four hours of HF-HD (estimated in vivo cutoff 15-20 kDa) in random order. Statistical methods and outcome measures: As data lacked normal distribution, we used nonparametric statistical analysis. Plasma and dialysate concentrations of beta2MG and albumin were measured at baseline and after four hours of each study treatment. MAIN FINDINGS: We found significantly greater diffusive beta2MG clearances for HCO-HD compared to HF-HD (at the start: 71.8 ml/min vs. 5.1 ml/min; P=0.008 and at the end: 68.8 ml/min vs. 5.7 ml/min; P=0.008). We found a reduction in plasma beta2MG concentrations of -31.6% during HCO-HD compared to an increase by 25.7% during HF-HD; P=0.008. At baseline (HCO-HD: 26.0 g/L vs. HF-HD: 26.5 g/L), and at the end of both treatments, plasma albumin concentrations were comparable (HCO-HD: 25.5 g/L vs. HF-HD: 26.5 g/L; P=0.25). During HCO-HD, albumin clearance was 1.9 ml/min at the start and decreased significantly to 0.8 ml/min at the end; P=0.008. HF-HD had an albumin clearance of 0.01 ml/min. CONCLUSIONS: HCO-HD was more effective in decreasing plasma beta2MG concentrations than standard HF-HD and did not reduce plasma albumin levels. Further studies of HCO-HD in the treatment of dialysis-related beta2MG accumulation appear warranted.

Asunto(s)

Lesión Renal Aguda/terapia , Diálisis Renal , Albúmina Sérica/análisis , Microglobulina beta-2/sangre , Lesión Renal Aguda/sangre , Adulto , Anciano , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Diálisis Renal/métodos

RESUMEN

Using a large, international cohort, we sought to determine the effect of initial technique of renal replacement therapy (RRT) on the outcome of acute renal failure (ARF) in the intensive care unit (ICU). We enrolled 1218 patients treated with continuous RRT (CRRT) or intermittent RRT (IRRT) for ARF in 54 ICUs in 23 countries. We obtained demographic, biochemical and clinical data and followed patients to either death or hospital discharge. Information was analyzed to assess the independent impact of treatment choice on survival and renal recovery. Patients treated first with CRRT (N=1006, 82.6%) required vasopressor drugs and mechanical ventilation more frequently compared to those receiving IRRT (N=212, 17.4%), (p<0.0001). Unadjusted hospital survival was lower (35.8% vs. 51.9%, p<0.0001). However, unadjusted dialysis-independence at hospital discharge was higher after CRRT (85.5% vs. 66.2%, p<0.0001). Multivariable logistic regression showed that choice of CRRT was not an independent predictor of hospital survival or dialysis-free hospital survival. However, the choice of CRRT was a predictor of dialysis independence at hospital discharge among survivors (OR: 3.333, 95% CI: 1.845 - 6.024, p<0.0001). Further adjustment using a propensity score did not significantly change these results. We conclude that worldwide, the choice of CRRT as initial therapy is not a predictor of hospital survival or dialysis-free hospital survival but is an independent predictor of renal recovery among survivors.

Asunto(s)

Lesión Renal Aguda/terapia , Enfermedad Crítica , Diálisis Renal/métodos , Lesión Renal Aguda/fisiopatología , Anciano , Causas de Muerte , Estudios de Cohortes , Cuidados Críticos , Femenino , Estudios de Seguimiento , Predicción , Humanos , Riñón/fisiopatología , Masculino , Persona de Mediana Edad , Alta del Paciente , Estudios Prospectivos , Recuperación de la Función/fisiología , Respiración Artificial , Tasa de Supervivencia , Resultado del Tratamiento , Vasoconstrictores/uso terapéutico

RESUMEN

OBJECTIVES: To review the literature on the experimental, physiological and clinical effects of blood purification with high cut-off (HCO) point membranes in septic acute renal failure (ARF). STUDY DESIGN: MEDLINE and PubMed database search combining relevant terms and integrating data from studies on the use of HCO membranes. SETTING AND POPULATION: Ex vivo studies of endotoxemia, animal studies of bacteremia and clinical studies using HCO membranes in patients with septic ARF. SELECTION CRITERIA FOR STUDIES: Original data from primary publications. INTERVENTIONS: HCO membrane-based hemodialysis, hemodiafiltration or hemofiltration. OUTCOMES: Plasma cytokine clearance, immunological and physiological effects and safety parameters of HCO membranes. RESULTS: HCO membranes effectively remove cytokines from blood. Treatment using HCO membranes has beneficial effects on immune cell function and increases survival in animal models of sepsis. Preliminary clinical studies show that HCO membranes decrease plasma cytokine levels and the need for vasopressor therapy. HCO membrane-based blood purification has now been applied in four pilot randomized controlled studies of 70 patients with septic ARF with no reports of serious adverse effects. LIMITATIONS: Because of substantial heterogeneity, no formal quantitative analysis could be performed. CONCLUSIONS: The available evidence on HCO blood purification justifies larger randomized controlled trials in patients with septic ARF.

Asunto(s)

Lesión Renal Aguda/complicaciones , Lesión Renal Aguda/terapia , Membranas Artificiales , Diálisis Renal , Sepsis/complicaciones , Humanos

RESUMEN

Contrast ultrasound is a promising and straightforward method that is superior to established sonographic techniques such as conventional B-mode scanning which is used for volume measurement and hematoma demonstration. Color Doppler is important for the evaluation of rejection, the detection of perfusion defects, and complete vascularization in the diagnostic evaluation of kidney grafts. Moreover, contrast US has the potential for tumor characterization in transplanted kidneys. A single examination by contrast ultrasound can answer a variety of questions with respect to the early postoperative phase and chronic damage. New applications of contrast US will arise from the further technical development of ultrasound equipment. The rapid technical advances seen in recent years have been followed by the introduction of new software tools for the analysis of raw datasets or the improved visualization of microbubbles at very low energy. Initial studies show that efficient and early diagnosis of rejection is possible. Surgical complications like perfusion defects or hematoma can also be identified.

Asunto(s)

Medios de Contraste , Rechazo de Injerto/diagnóstico por imagen , Aumento de la Imagen , Trasplante de Riñón/diagnóstico por imagen , Microburbujas , Fosfolípidos , Hexafluoruro de Azufre , Ultrasonografía Doppler en Color , Animales , Biopsia , Modelos Animales de Enfermedad , Rechazo de Injerto/patología , Hematoma/diagnóstico por imagen , Hematoma/etiología , Hematoma/patología , Humanos , Procesamiento de Imagen Asistido por Computador , Riñón/irrigación sanguínea , Riñón/patología , Corteza Renal/patología , Enfermedades Renales/diagnóstico por imagen , Enfermedades Renales/etiología , Enfermedades Renales/patología , Trasplante de Riñón/patología , Complicaciones Posoperatorias/diagnóstico por imagen , Periodo Posoperatorio , Programas Informáticos , Factores de Tiempo , Ultrasonografía Doppler en Color/métodos

RESUMEN

Ultrasound (US) imaging is an important diagnostic tool following renal transplantation. Unfortunately, due to the heterogeneity of the recipients and their multimorbidity, imaging procedures in the early phase after kidney transplantation are difficult and of limited use. We performed a study to evaluate the use of a contrast enhancer for US examination as a standardized method in the follow-up of kidney transplant recipients.The study included 40 recipients: 32 were examined on the 5th to 7th day following transplantation and 8 patients at the time when clinically suspicious findings occurred (acute rejection, tumor, acute tubular necrosis). Following the intravenous application of the contrast medium, pictures were taken during the arterial and parenchymatous phase and compared with conventional B-mode and power Doppler pictures of the same visual plane. Three examiners assessed different parameters of the transplant organ (max. vascularized area, suspected hematomas, tumors, rejection, acute tubular necrosis). Findings were confirmed by histological results of a biopsy if rejection, tumor, or acute tubular necrosis were suspected. Application of ultrasound contrast medium significantly increased visualization of the vascularized kidney area. Also, US findings in the follow-up after acute rejection therapy corresponded with the clinical course; 19 hematomas could be detected with contrast medium compared to only 9 without. With contrast medium a perfusion deficit was detectable in three patients compared to one patient with power Doppler US. Also, US contrast medium helped to detect tumor vascularization in two patients in whom conventional sonography suspected no abnormality. Ultrasound contrast medium enhancement is a reproducible, reliable, and easy to apply method which is superior to conventional sonography in the follow-up after kidney transplantation. This method is also helpful to detect and control acute rejections and to better visualize hematomas, deficits of perfusion, and tumors.

Asunto(s)

Rechazo de Injerto/diagnóstico por imagen , Necrosis de la Corteza Renal/diagnóstico por imagen , Neoplasias Renales/diagnóstico por imagen , Trasplante de Riñón/diagnóstico por imagen , Adolescente , Adulto , Anciano , Ecocardiografía/normas , Femenino , Alemania , Rechazo de Injerto/etiología , Humanos , Necrosis de la Corteza Renal/etiología , Neoplasias Renales/etiología , Trasplante de Riñón/efectos adversos , Masculino , Persona de Mediana Edad , Cuidados Posoperatorios/métodos , Cuidados Posoperatorios/normas , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/normas , Pronóstico , Reproducibilidad de los Resultados , Medición de Riesgo/métodos , Sensibilidad y Especificidad

RESUMEN

Diuretic therapy in ARF (acute renal failure) is mainly done with loop diuretics, first of all furosemide. Torsemide has a longer duration of action and does not accumulate in renal failure. In chronic and acute renal failure, both diuretics have been effectively applied, with a more pronounced diuretic effect for torsemide. In this study, the effects of torsemide versus furosemide on renal function in cardiac surgery patients recovering from ARF after continuous renal replacement therapy (CRRT) were studied. Twenty-nine critically ill patients admitted to an intensive care unit at a university teaching hospital after cardiac surgery recovering from ARF after CRRT were included in this prospective, controlled, single-center, open-labeled, randomized clinical trial. Inclusion criteria were urine output >0.5 mL/kg/h over 6 h under CRRT. Torsemide and furosemide dosages were adjusted with the target urine output being 0.8-1.5 mL/kg/h. Hemodynamic data, urine output, volume balance, serum creatinine clearance, electrolytes, blood urea nitrogen, serum creatinine, renin, and aldosterone concentrations were measured. Fourteen patients were included in the furosemide group and 15 patients in the torsemide group. Dosages of 29 (0-160) mg torsemide and a dosage of 60 (0-240) mg furosemide were given every 6 h in each group, respectively. The dosage given at the end of the study decreased significantly in furosemide and torsemide treated patients. Urine output, 24 h balance, and serum creatinine clearance did not differ significantly between groups. Urine output decreased in both groups, mostly dose-dependent in the torsemide group. The intragroup comparison of the first time-interval after inclusion with the last time-interval showed a significant increase in serum creatinine and blood urea nitrogen in the furosemide group. Renin and aldosterone concentrations did not show significant differences. In conclusion, torsemide and furosemide were effective in increasing urine output. Torsemide might show a better dose-dependent diuretic effect in ARF patients after CRRT treatment. Serum creatinine and blood urea nitrogen elimination were less pronounced in the furosemide group.

Asunto(s)

Lesión Renal Aguda/tratamiento farmacológico , Furosemida/administración & dosificación , Diálisis Renal/métodos , Sulfonamidas/administración & dosificación , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/terapia , Adulto , Anciano , Distribución de Chi-Cuadrado , Terapia Combinada , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Pruebas de Función Renal , Masculino , Persona de Mediana Edad , Probabilidad , Estudios Prospectivos , Valores de Referencia , Medición de Riesgo , Índice de Severidad de la Enfermedad , Método Simple Ciego , Estadísticas no Paramétricas , Torasemida , Resultado del Tratamiento

RESUMEN

BACKGROUND AND OBJECTIVES: The removal of cytokines by standard hemofiltration is limited. Super high flux membranes may significantly improve removal even when used in dialysis mode. We sought to measure cytokine clearance using a large surface super high-flux membrane and a standard hemodialysis setting. SETTING: ICU laboratory of a tertiary institution. SUBJECTS: Six healthy volunteers. METHODS: Blood form healthy volunteers was incubated for 4 hours with E. coli endotoxin to stimulate cytokine production. Cytokine containing blood was then circulated through a dialysis circuit at 3 different dialysate flow rates. Blood and dialysate were sampled for cytokine and albumin measurements and calculation of clearances. RESULTS: Super high-flux dialysis achieved high median cytokine clearances (IL-1 clearance of 106 ml/min, IL-6 clearance of 66.8 ml/min, IL-8 clearance of 61.7 ml/min and TNF clearance of 36.1 ml/min). Increasing dialysate flow rate from 300 to 500 ml/min did not significantly increase cytokine clearances. Albumin clearances however were between 2.7 and 5.4 ml/min. CONCLUSIONS: Cytokine dialysis is feasible at high dialysate flow rates yielding high cytokine clearances. Albumin loss, however, is appreciable and may require separate supplementation in the clinical setting.

Asunto(s)

Citocinas/aislamiento & purificación , Membranas Artificiales , Diálisis Renal/métodos , Albúminas/metabolismo , Hemodiafiltración/métodos , Humanos , Técnicas In Vitro , Interleucina-1/aislamiento & purificación , Interleucina-6/aislamiento & purificación , Interleucina-8/aislamiento & purificación , Filtros Microporos , Valores de Referencia , Diálisis Renal/instrumentación , Proyectos de Investigación , Factor de Necrosis Tumoral alfa/aislamiento & purificación

RESUMEN

BACKGROUND: Beta2m accumulation induces disease in patients with end-stage renal failure (ESRF). Thus, its removal from patients with ESRF appears desirable. Current dialysis technology, however, has limited effectiveness. AIMS: To measure beta2m clearance with a novel super high flux membrane. DESIGN: Ex vivo experimental study. SETTING: Intensive Care Laboratory of Tertiary institution. SUBJECTS: Six volunteers. MEASUREMENTS AND RESULTS: At a blood flow of 300 ml/min, the clearance of beta2-MG increased from 113.5 +/- 38.5 ml/min with a dialysate flow rate of 200 ml/min to 184.8 +/- 61.1 ml/min with a flow rate of 300 ml/min and 195.0 +/- 60.0 ml/min with a 500 ml/min flow rate. The clearance of albumin was 4.5 ml/min with a dialysate flow rate of 200 ml/min, 5.2 ml/min for a flow rate of 300 ml/min and 5.8 ml/min for a flow rate of 500 ml/min. CONCLUSIONS: High levels of beta2m clearance can be achieved with a super high flux membrane while albumin losses remain limited.

Asunto(s)

Fallo Renal Crónico/sangre , Fallo Renal Crónico/terapia , Diálisis Renal/métodos , Microglobulina beta-2/sangre , Intervalos de Confianza , Humanos , Membranas Artificiales

RESUMEN

MARS stands for Molecular Adsorbent Recirculating System and represents an interesting option in treating patients with liver disease. There is still little known about the best time point of initiating this treatment and the exact selection criteria for patients who may benefit from this therapy. The list of potential applications using this procedure is expanding. We report on the experience in seven patients being treated with MARS dialysis for chronic cholestatic liver disease and acute on chronic liver failure. From August 2000 to October 2001 seven patients received 27 MARS treatments in our clinic, ranging from 2 to 12 treatments per subject. Presented cases were diagnosed as steatohepatitis because of alcoholism (n = 3), vanishing bile duct disease (n = 1), metabolic liver disease (n = 1), primary biliary cirrhosis (n = 1) and drug-induced hepatitis (n = 1). Based on this experience, we discuss the ongoing questions of various indications and the decision to initiate MARS dialysis.

Asunto(s)

Fallo Hepático Agudo/terapia , Diálisis Renal , Desintoxicación por Sorción , Adulto , Anciano , Enfermedad Hepática Inducida por Sustancias y Drogas/terapia , Hígado Graso Alcohólico/terapia , Femenino , Humanos , Cirrosis Hepática Biliar/terapia , Masculino , Persona de Mediana Edad

Asunto(s)

Albúminas/uso terapéutico , Soluciones para Diálisis/uso terapéutico , Rechazo de Injerto/terapia , Trasplante de Hígado/efectos adversos , Diálisis Renal/instrumentación , Anciano , Rechazo de Injerto/etiología , Humanos

RESUMEN

Proctocolectomy with ileal pouch-anal anastomosis and temporary ileostomy has been established as a curative operation in severe ulcerative colitis during the last 2 decades. Electrolyte imbalances during the first postoperative weeks until ileostomy closure have been reported previously. Here we report about a 70-year-old male patient with a 38 year-history of severe ulcerative colitis who developed slowly progressive renal failure after proctocolectomy with ileal pouch-anal anastomosis and temporary ileostomy. He was referred to our centre with a serum creatinine of 818 micromol/L, hypokalemia of 2.83 mmol/L and metabolic alkalosis as a patient with suspected end-stage renal disease in order to perform shunt surgery and start chronic hemodialysis. However, hypokalemia and metabolic alkalosis are not typical for end-stage renal disease, and renal biopsy showed typical signs of hypokalemic nephropathy. Our patient almost completely recovered after ileostomy closure. This case clearly shows that temporary ileostomy in patients who underwent proctocolectomy, e. g. for ulcerative colitis, is associated with a risk of hypokalemic nephropathy. The appropriate and definite therapy is a surgical one, i. e. ileostomy closure. Monitoring metabolic changes after proctocolectomy and ileostomy, especially during the defunctionalized stage when temporary ileostomy is still present, is essential.

Asunto(s)

Colitis Ulcerosa/cirugía , Hipopotasemia/etiología , Ileostomía , Fallo Renal Crónico/etiología , Complicaciones Posoperatorias/etiología , Proctocolectomía Restauradora , Adulto , Biopsia , Colitis Ulcerosa/patología , Humanos , Hipopotasemia/patología , Fallo Renal Crónico/patología , Pruebas de Función Renal , Túbulos Renales/patología , Masculino , Complicaciones Posoperatorias/patología , Factores de Riesgo

RESUMEN

OBJECTIVE: To compare the efficacy and safety of hirudin and heparin for anticoagulation during continuous renal replacement therapy (CRRT) in critically ill patients. DESIGN: Prospective, randomized controlled pilot study. SETTING: Single centre; interdisciplinary intensive care unit at a university hospital. PATIENTS: Seventeen patients receiving CRRT. INTERVENTIONS: Patients were randomly allocated to two groups. Heparin group (nine patients): continuous administration of 250 IU/h heparin; dose was adjusted in 125 IU/h steps with a targeted activated clotting time (ACT) of 180-210 s. Hirudin group (eight patients): continuous infusion of 10 micrograms/kg/h hirudin, dose was adjusted in 2 micrograms/kg/h steps with a targeted ecarin clotting time (ECT) of 80-100 s. Observation time was 96 h. MEASUREMENTS AND MAIN RESULTS: Measured filter run patency and haemofiltration efficacy did not significantly differ between the two groups. Three bleeding complications were observed in the hirudin group, none in the heparin group (P < 0.01). At the onset of bleeding, which occurred 60 or more hours after the start of therapy, only one patient was still under continuous hirudin administration but levels were either in therapeutic range or below. CONCLUSIONS: Hirudin can be used efficiently for anticoagulation in CRRT. Late bleeding complications may have been caused by possible hirudin accumulation, but this was not evident from hirudin plasma and ECT levels. Since bleeding complications were observed only in the presence of documented coagulation disorders, not only adequate drug monitoring but also the plasmatic and cellular coagulation status of the patient should be taken into consideration for adjusting hirudin dosage.

Asunto(s)

Lesión Renal Aguda/terapia , Anticoagulantes/uso terapéutico , Heparina/efectos adversos , Heparina/uso terapéutico , Terapia con Hirudina , Hirudinas/efectos adversos , Terapia de Reemplazo Renal , APACHE , Lesión Renal Aguda/sangre , Adulto , Anciano , Anciano de 80 o más Años , Trastornos de la Coagulación Sanguínea/sangre , Trastornos de la Coagulación Sanguínea/etiología , Pruebas de Coagulación Sanguínea , Terapia Combinada , Femenino , Hemorragia/sangre , Hemorragia/etiología , Humanos , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica

Asunto(s)

Huesos/diagnóstico por imagen , Huesos/patología , Glucocorticoides/efectos adversos , Metilprednisolona/efectos adversos , Osteoporosis/inducido químicamente , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Osteoporosis/diagnóstico , Osteoporosis/diagnóstico por imagen , Cintigrafía

RESUMEN

OBJECTIVES: The objective of our study was to assess the hemodynamic effects of immunoadsorption (IA) and subsequent immunoglobulin G (IgG) substitution in comparison with the effects of conventional medical treatment in patients with dilated cardiomyopathy (DCM). BACKGROUND: Various circulating cardiac autoantibodies have been detected among patients suffering from DCM. These antibodies are extractable by IA. METHODS: Patients with DCM (n = 18, New York Heart Association III-IV, left ventricular ejection fraction <30%) and who were on stable medication participated in the study. Hemodynamic measurements were performed using a Swan-Ganz thermodilution catheter. The patients were randomly assigned either to the treatment group with IA and subsequent IgG substitution (IA/IgG group, n = 9) or to the control group without IA/IgG (n = 9). In the IA/IgG group, the patients were initially treated in one IA session daily on three consecutive days. After the final IA session, 0.5 g/kg of polyclonal IgG was substituted. At one-month intervals, IA was then repeated for three further courses with one IA session daily on two consecutive days, until the third month. RESULTS: After the first IA course and IgG substitution, cardiac index (CI) increased from 2.1 (+/-0.1) to 2.8 (+/-0.1) L/min/m2 (p < 0.01) and stroke volume index (SVI) increased from 27.8 (+/-2.3) to 36.2 (+/-2.5) ml/m2 (p < 0.01). Systemic vascular resistance (SVR) decreased from 1,428 (+/-74) to 997 (+/-55) dyne x s x cm(-5) (p < 0.01). The improvement in CI, SVI and SVR persisted after three months. In contrast, hemodynamics did not change throughout the three months in the control group. CONCLUSIONS: Immunoadsorption and subsequent IgG substitution improves cardiovascular function in DCM.

Asunto(s)

Cardiomiopatía Dilatada/terapia , Hemodinámica/fisiología , Inmunoglobulina G/administración & dosificación , Técnicas de Inmunoadsorción , Adulto , Autoanticuerpos/sangre , Cardiomiopatía Dilatada/inmunología , Humanos , Inmunoglobulina G/sangre , Masculino , Persona de Mediana Edad , Miocardio/inmunología , Volumen Sistólico/fisiología , Función Ventricular Izquierda/fisiología